GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
This article was originally published in PharmAsia News
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
You may also be interested in...
Sanofi And Korea’s Hanmi Ink Co-marketing Deal That Could See Sanofi Selling Hanmi’s Irbestin Abroad
Sanofi and Korea’s Hanmi sign a co-marketing agreement that may see both companies marketing Hanmi’s fixed-dose combination products beyond Korea.
The domestic pharma, in which GSK holds a minority stake, won a key battle with the government while its Korean peer Chong Kun Dang lost a similar case and saw 16 drugs take a price cut.
Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates
As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.